Development of novel ligands for peptide GPCRs

Research output: Contribution to journalArticle

11 Citations (Scopus)
52 Downloads (Pure)

Abstract

Incretin based glucagon-like peptide-1 receptor (GLP-1R) agonists which target a G-protein coupled receptor (GPCR) are currently used in the treatment of type 2 diabetes. This review focuses on GPCRs from pancreatic b-cells, including GLP-1, glucose-dependent insulinotropic polypeptide (GIP), glucagon, somatostatin, pancreatic polypeptide (PP), cholecystokinin (CCK), peptide YY (PYY), oxyntomodulin (OXM) and ghrelin receptors. In addition, fatty acids GPCRs are thought to have an increasing role in regulating peptide secretions namely short fatty acids GPCR (GPR41, GPR43), medium chain fatty acid GPCR (GPR84), long chain fatty acid GPCR (GPR40, GPR120) and cannabinoid-like GPCR (GPR55, GPR119). Several preclinical and clinical trials are currently ongoing in peptide GPCR based therapies, including dual and triple agonist peptides which activate two or more GPCRs simultaneously.
Original languageEnglish
Pages (from-to)57-62
JournalCurrent Opinion in Pharmacology
Volume31
Early online date5 Sep 2016
DOIs
Publication statusPublished - 1 Dec 2016

Keywords

  • GPCR
  • beta-cells

Fingerprint Dive into the research topics of 'Development of novel ligands for peptide GPCRs'. Together they form a unique fingerprint.

Cite this